Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 5Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 207fludarabine phosphate 182Azacitidine 153fludarabine 141Busulfan 139Tacrolimus 118Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 105Peripheral Blood Stem Cell Transplantation 97Antilymphocyte Serum 95Melphalan 89Filgrastim 86Cyclosporine 81Methotrexate 78Decitabine 78venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 46Cord Blood Stem Cell Transplantation 43thymoglobulin 41Clofarabine 41Etoposide 35Specimen Handling 34Methylprednisolone 34Sirolimus 33Biopsy 27Injections 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × talazoparib × Other hematologic neoplasm × Clear all
NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Pfizer

Phase 1 Completed
33 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡